Updates on 2L Metastatic Breast Cancer Management for PIK3CA/AKT/PTEN Alteration
Updates on 2L metastatic breast cancer management for PIK3CA/AKT/PTEN alteration Featured Expert Panel: • Dr. Shaheenah Dawood (UAE) - Moderator • Dr. Peter Fasching (Germany) • Dr. Ahmed Ali Obaya (Bahrain) • Dr. Maha El Sindi (Bahrain) • Dr. Sinem Akbas (Bahrain) • Dr. Ozge Keskin (Bahrain) • Dr. Tarkan Yetisyigit (Bahrain)
▶︎
Management of aBC patients post CDK4/6i
▶︎
Food is medicine - closing the gap on malnutrition with a new ISO standard for hospitals
▶︎
ASCO 2026 Highlights Panel Discussion | Dana-Farber Cancer Institute
▶︎
From Advanced to Early Breast Cancer: CDK4/6i Overview
▶︎
Webinar: Reducing Maternal Morbidity and Mortality in Ontario
▶︎
Doctor reveals undisclosed risks of COVID-19 vaccine
▶︎
Rewiring the Brain: The Promise and Peril of Neuroplasticity | World Science Festival
▶︎
Use These 5 Food Hacks To Heal The Body & STARVE CANCER I Dr. William Li
▶︎
Recent Advances and Future Treatment Landscape of Hr+ BC
▶︎
CDK4/6i: Post ASCO Updates
▶︎
Briefing Webinar, NHS Cancer Programme Innovation Open Call 4, June 2026
▶︎
The FDA Rejected This Breast Cancer Drug. Here's Why.
▶︎
Emerging OX40/OX40L–Targeted Therapies, Durable AD Control, and Enhanced Quality of Life
▶︎
Gut Expert: Eating these 3 foods could improve your mental health | Tim Spector: Full Interview
▶︎
Cardiovascular Issues and Other Comorbidities
▶︎
Evolving Paradigms: The Role of Immunotherapy Across the Lung Cancer Spectrum
▶︎
Cholestasis in pregnancy by Catherine Williamson (FMF 20.2.2026)
▶︎
Clear Margins… But Risk Remains
▶︎
Understanding CDK4/6 Inhibitors in Breast Cancer Treatment
▶︎